- Home
- BMEA vs CHPG Comparison
BMEA vs CHPG Comparison
Compare BMEA & CHPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- CHPG
- Stock Information
- Founded
- BMEA 2017
- CHPG 2024
- Country
- BMEA United States
- CHPG United States
- Employees
- BMEA 63
- CHPG N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- CHPG
- Sector
- BMEA Health Care
- CHPG
- Exchange
- BMEA Nasdaq
- CHPG Nasdaq
- Market Cap
- BMEA 96.9M
- CHPG 101.2M
- IPO Year
- BMEA 2021
- CHPG N/A
- Fundamental
- Price
- BMEA $1.36
- CHPG $10.13
- Analyst Decision
- BMEA Strong Buy
- CHPG
- Analyst Count
- BMEA 7
- CHPG 0
- Target Price
- BMEA $8.86
- CHPG N/A
- AVG Volume (30 Days)
- BMEA 1.7M
- CHPG 8.8K
- Earning Date
- BMEA 11-04-2025
- CHPG 07-23-2025
- Dividend Yield
- BMEA N/A
- CHPG N/A
- EPS Growth
- BMEA N/A
- CHPG N/A
- EPS
- BMEA N/A
- CHPG N/A
- Revenue
- BMEA N/A
- CHPG N/A
- Revenue This Year
- BMEA N/A
- CHPG N/A
- Revenue Next Year
- BMEA N/A
- CHPG N/A
- P/E Ratio
- BMEA N/A
- CHPG N/A
- Revenue Growth
- BMEA N/A
- CHPG N/A
- 52 Week Low
- BMEA $1.22
- CHPG $9.81
- 52 Week High
- BMEA $8.99
- CHPG $10.24
- Technical
- Relative Strength Index (RSI)
- BMEA 40.15
- CHPG N/A
- Support Level
- BMEA $1.22
- CHPG N/A
- Resistance Level
- BMEA $1.35
- CHPG N/A
- Average True Range (ATR)
- BMEA 0.10
- CHPG 0.00
- MACD
- BMEA 0.00
- CHPG 0.00
- Stochastic Oscillator
- BMEA 31.16
- CHPG 0.00
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About CHPG ChampionsGate Acquisition Corporation Class A Ordinary Share
Championsgate Acquisition Corp is a blank check company.